Metilprednisolon Rompharm (Methylprednisolone)

Methylprednisolone binds to intracellular glucocorticoid receptors, forming a complex that enters the nucleus and alters gene transcription. This reduces the production of inflammatory mediators, limits leukocyte migration, and suppresses immune cell activation, leading to decreased inflammation and immunosuppression.

The specific dose and dosing schedule of Metilprednisolon Rompharm are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Only a qualified healthcare professional should set the appropriate regimen.

Safety data for methylprednisolone in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Use only if the potential benefit justifies the potential risk to the fetus or infant, and discuss with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Methylprednisolone offers a potent anti‑inflammatory effect with a relatively rapid onset compared with some older glucocorticoids. Its pharmacokinetic profile allows both intravenous and intramuscular administration, providing flexibility for acute severe inflammation, whereas other corticosteroids may be limited to oral or specific parenteral routes.

Store the injectable solution at ambient temperature, below 25 °C, in the original packaging. Protect it from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and keep it out of reach of children.

Metilprednisolon Rompharm is supplied as an injectable solution for intramuscular or intravenous administration. The route, dose, and infusion rate are determined by the prescribing clinician and should be performed by qualified healthcare personnel in a controlled setting.

Serious risks include adrenal insufficiency if the drug is stopped abruptly, severe infections due to immunosuppression, gastrointestinal bleeding, osteonecrosis, and rare anaphylactic reactions. Patients should be monitored closely for signs of these complications throughout therapy.

Patients with known hypersensitivity to methylprednisolone or any component of the formulation should avoid use. Caution is also advised for individuals with uncontrolled infections, active tuberculosis, or those receiving live vaccines, as the drug can exacerbate these conditions.